Welcome to our dedicated page for BIOGEN SEC filings (Ticker: BIIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biogen Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company with commercial products and development programs in neurology, rare disease and immune-mediated conditions. Forms 8-K cover operating and financial results, product-revenue commentary, acquired in-process research and development, upfront and milestone expenses, collaboration and license-agreement costs, material agreements, capital-structure disclosures and clinical or regulatory updates.
Biogen’s proxy and governance filings address board leadership, director matters, executive compensation and annual meeting items. The filing record also documents the company’s common stock registered on The Nasdaq Global Select Market, officer and director transitions, risk-related forward-looking disclosures and transaction communications tied to strategic business development activity.
Godbout Sean reported acquisition or exercise transactions in this Form 4 filing.
Biogen Inc. Chief Accounting Officer Sean Godbout reported receiving a grant of 1,800 restricted stock units. These RSUs were awarded at a stated price of $0.00 per unit and increase his directly owned derivative holdings to 1,800 units. According to the footnote, the award vests in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026, meaning one-third of the units will vest each year over a three-year period.
ALEXANDER SUSAN H reported acquisition or exercise transactions in this Form 4 filing.
BIOGEN INC. reported that EVP and Chief Legal Officer Susan H. Alexander received a grant of 8,450 restricted stock units on February 13, 2026. These units represent a form of equity compensation rather than a cash transaction. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the February 13, 2026 grant date, meaning the award is earned over time as continued service is provided.
Biogen Inc. announced a planned change in its Board leadership. Caroline Dorsa, current Chair of the Board of Directors, informed the company that she will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company states that her decision is not related to any disagreement with the Board or Biogen regarding operations, policies, or practices.
On the same date, Biogen’s Board elected Dr. Maria C. Friere to serve as Chair of the Board, effective after the 2026 Annual Meeting. This provides for an orderly transition in the role of Board Chair following the shareholder meeting.
Biogen Inc. President and CEO Christopher Viehbacher reported multiple equity transactions on February 6, 2026 as restricted stock units converted into common shares and a portion of the new shares was withheld for taxes.
He acquired 9,008 and 15,453 shares of Biogen common stock at an exercise price of $0 through the vesting and settlement of previously granted restricted stock units. To satisfy tax obligations tied to these vestings, 4,356 shares and 6,624 shares were automatically withheld at a price of $201.18 per share. After these transactions, he directly owned 29,924 shares of common stock, along with 9,009 and 30,907 restricted stock units that continue to vest in three equal annual installments from their respective 2024 and 2025 grant dates.
Biogen Inc.’s Head of Development, Priya Singhal, reported multiple equity transactions in early February 2026. On February 6, 2026, she exercised restricted stock units into 2,217 and 4,683 shares of common stock at an exercise price of $0 per share. To cover associated obligations, 1,056 and 1,412 shares of common stock were withheld at $201.18 per share. On February 9, 2026, she sold 2,660 common shares at $199.83 per share, leaving 8,043.1428 common shares owned directly and 9,367 restricted stock units outstanding that vest in three annual installments from 2024 and 2025 grant dates.
Biogen Inc. executive Nicole Murphy, Head of Pharm Ops and Tech, reported multiple equity transactions dated 02/06/2026. Several tranches of restricted stock units converted into common stock, including 2,102, 1,940 and 4,683 units, each at an exercise price of $0.
To cover related tax obligations, common shares were withheld at $201.18 per share in amounts of 1,017, 914 and 1,408 shares. Following these transactions, Murphy directly beneficially owned 19,608.0408 shares of Biogen common stock, which includes 166.6667 shares acquired under the Biogen employee stock purchase plan on 3/31/2025.
Biogen Inc. Chief Financial Officer Robin Kramer reported several stock transactions dated February 6, 2026 related to vesting of restricted stock units (RSUs). RSU awards for 789, 703 and 3,511 units were converted into an equal number of Biogen common shares at an exercise price of $0.
To cover tax obligations on these vestings, Kramer had 273, 207 and 1,063 Biogen common shares withheld or disposed of at a transaction price of $201.18 per share. After these transactions, Kramer directly beneficially owned 11,471.7483 shares of Biogen common stock and continued to hold RSUs that vest in three equal annual installments under prior grants.
Biogen Inc. Head of Corporate Development Adam Keeney reported multiple equity transactions dated February 6, 2026. He acquired 1,802 and 3,278 shares of common stock at $0 per share through the exercise of restricted stock units, then disposed of 589 and 994 shares at $201.18 per share.
Following these transactions, Keeney directly beneficially owned 5,881 shares of Biogen common stock and 6,557 restricted stock units. The restricted stock units referenced in the filing vest in three equal annual installments starting one year after their respective grant dates in 2024 and 2025.
Biogen officer Rachid Izzar, Head of Global Product Strategy, reported multiple transactions on common stock tied to vested restricted stock units on February 6, 2026. Several RSU awards were exercised at an exercise price of $0 per share and converted into Biogen common stock.
In connection with these vestings, shares were automatically withheld at $201.18 per share to cover tax obligations, rather than sold on the open market. After these transactions, Izzar directly owned 11,011 shares of Biogen common stock. Footnotes explain that the underlying RSU grants vest in three equal annual installments starting one year after grant dates in 2023, 2024, and 2025.
Biogen Inc. Head of Research Jane Grogan reported equity compensation activity on February 6, 2026. She converted 1,385 and 1,873 restricted stock units into common stock at an exercise price of $0 per share and had shares withheld to cover taxes at $201.18 per share.
After these transactions, she directly owned 4,058 shares of Biogen common stock and 3,747 restricted stock units. One RSU grant vests in three equal annual installments starting one year after the February 7, 2024 grant date, and another vests in three yearly installments beginning on the first anniversary of the February 6, 2025 grant date.